Mitsubishi UFJ Trust & Banking Corp reduced its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,516 shares of the company's stock after selling 3,026 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.08% of BioNTech worth $21,367,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the stock. LPL Financial LLC increased its stake in BioNTech by 4.9% during the 4th quarter. LPL Financial LLC now owns 38,860 shares of the company's stock valued at $4,428,000 after buying an additional 1,800 shares during the period. Lingohr Asset Management GmbH acquired a new position in shares of BioNTech during the fourth quarter valued at approximately $357,000. Midwest Professional Planners LTD. increased its stake in shares of BioNTech by 5.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after acquiring an additional 222 shares during the period. LBP AM SA raised its holdings in BioNTech by 2.1% during the fourth quarter. LBP AM SA now owns 252,918 shares of the company's stock worth $28,820,000 after purchasing an additional 5,085 shares in the last quarter. Finally, Vestcor Inc lifted its position in BioNTech by 50.0% in the fourth quarter. Vestcor Inc now owns 9,900 shares of the company's stock worth $1,128,000 after purchasing an additional 3,300 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Stock Down 0.8 %
NASDAQ:BNTX traded down $0.77 during trading hours on Tuesday, hitting $90.29. 1,140,687 shares of the company's stock traded hands, compared to its average volume of 832,894. The stock's fifty day moving average price is $110.45 and its two-hundred day moving average price is $113.41. The firm has a market cap of $21.67 billion, a P/E ratio of -43.00 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 EPS. On average, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
BNTX has been the topic of several research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright lowered their target price on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Tuesday. Citigroup assumed coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target for the company. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Finally, Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.
Get Our Latest Analysis on BioNTech
BioNTech Company Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
See Also
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
